CA
LTRN icon

Corriente Advisors’s Lantern Pharma LTRN Stock Holding History

Corriente Advisors’s Portfolio LTRN Stock Details LTRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-625,873
Closed -$7M – 7
2021
Q3 		$7M Sell
625,873
-30,491
-5% -$395K 13.51% 4
2021
Q2 		$9.58M Sell
656,364
-57,442
-8% -$887K 5.17% 7
2021
Q1 		$12.9M Buy
+713,806
New +$12.5M 4.77% 8

Other funds holding LTRN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SMH
Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
LCM
Lynwood Capital Management Toronto, Ontario, Canada $16.9M AUM 19.31% 1-Year Est. Return
RAM
Redmond Asset Management Henrico, Virginia $366M AUM 10.64% 1-Year Est. Return

Corriente Advisors's LTRN Position: Q4 2021 in Review

Corriente Advisors sold out of Lantern Pharma (LTRN) in Q4 2021, closing a stake of 625,873 shares — an estimated $7M sold.

Corriente Advisors first reported a position in LTRN in Q1 2021 and held it in 3 quarters. The position peaked at $12.9M in Q1 2021. 33 funds tracked by Wall St. Rank hold LTRN as of Q4 2021.

  • Corriente Advisors reported no remaining Lantern Pharma position as of Q4 2021 after selling out during the quarter.
  • Corriente Advisors sold 625,873 Lantern Pharma shares in Q4 2021, an estimated $7M.
  • Corriente Advisors first reported a position in Lantern Pharma in Q1 2021 and held it in 3 quarters.
  • Corriente Advisors's Lantern Pharma position peaked at $12.9M in Q1 2021.
  • 33 funds tracked by Wall St. Rank held Lantern Pharma as of Q4 2021.

Based on Corriente Advisors's 13F filing for Q4 2021, filed 15 Feb 2022.